.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
US Department of Justice
UBS
Novartis
AstraZeneca
Julphar
US Army
QuintilesIMS
Federal Trade Commission
Cipla

Generated: July 23, 2017

DrugPatentWatch Database Preview

NEOPROFEN Drug Profile

« Back to Dashboard

Which patents cover Neoprofen, and when can generic versions of Neoprofen launch?

Neoprofen is a drug marketed by Recordati Rare and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has twelve patent family members in six countries.

The generic ingredient in NEOPROFEN is ibuprofen lysine. There are sixty-four drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the ibuprofen lysine profile page.

Summary for Tradename: NEOPROFEN

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list164
Clinical Trials: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NEOPROFEN at DailyMed

Pharmacology for Tradename: NEOPROFEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Recordati Rare
NEOPROFEN
ibuprofen lysine
INJECTABLE;INTRAVENOUS021903-001Apr 13, 2006APRXYesYes8,415,337► SubscribeYY ► Subscribe
Recordati Rare
NEOPROFEN
ibuprofen lysine
INJECTABLE;INTRAVENOUS021903-001Apr 13, 2006APRXYesYes6,344,479► SubscribeYYY ► Subscribe
Recordati Rare
NEOPROFEN
ibuprofen lysine
INJECTABLE;INTRAVENOUS021903-001Apr 13, 2006APRXYesYes6,342,530► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: NEOPROFEN

Drugname Dosage Strength RLD Submissiondate
ibuprofen lysineInjection10 mg/mL, 2 mL vialNeoprofen10/1/2010

International Patent Family for Tradename: NEOPROFEN

Country Document Number Estimated Expiration
Japan2002326929► Subscribe
European Patent Office1205181► Subscribe
Austria318136► Subscribe
MexicoPA02003033► Subscribe
European Patent Office1249234► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Harvard Business School
Boehringer Ingelheim
Julphar
Chinese Patent Office
Deloitte
Citi
Mallinckrodt
Moodys
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot